# LONG-TERM SAFETY, TOLERABILITY AND EFFECTIVENESS OF WEEKLY AND MONTHLY BUPRENORPHINE DEPOTS FOR OPIOID USE DISORDER

**Authors:**
NICHOLAS LINTZERIS[1,2], ADRIAN J. DUNLOP[3,4], PAUL HABER[2.5], ROBERT ALI[6], SONNIE KIM[8] and FREDRIK TIBERG[9]

[1] *South Eastern Sydney Local Health District Drug and Alcohol Service, Sydney, Australia.*
[2] *The University of Sydney, Sydney, New South Wales, Australia*
[3] *Hunter New England Local Health District Drug and Alcohol Clinical Services, Newcastle, Australia.*
[4] *School of Medicine and Public Health, University of Newcastle*
[5] *Sydney Local Health District Drug and Alcohol Service, Sydney, Australia.*
[6] *University of Adelaide, Adelaide, SA*
[4] *Braeburn Pharmaceuticals, New Jersey, USA*
[5] *Camurus AB, Lund, Sweden*

Presenter's email: Nicholas.Lintzeris@health.nsw.gov.au

**Introduction and Aims:**
To demonstrate long-term safety and local tolerability and evaluate efficacy of CAM2038 in adults with moderate-to-severe opioid use disorder (OUD). Weekly and monthly buprenorphine depots may improve treatment adherence and outcomes and reduce diversion and misuse compared with daily medications.

**Design and Methods:**
This multinational open-label, flexible dosing study enrolled participants, conducted in Europe, North America and Australia, either seeking or currently in OUD treatment, to individualized outpatient treatment with CAM2038. The study included screening, 48-weeks of treatment and 4 weeks of follow-up. Safety and local tolerability, urinalysis, self-report of drug use, craving, withdrawal and other outcome measures were collected.

**Results:**
A total of 227 participants were enrolled and dosed with CAM2038 of which 73.6% completed the study treatment period. Overall, 66.0% experienced any treatment emergent adverse event (TEAE), mostly mild to moderate intensity. No serious TEAEs (6.6%) were considered related to study drug, The safety profile of CAM2028 was generally consistent with the known safety profile of buprenorphine, except for mild to moderate injection site reactions (20.3%). Efficacy was generally maintained or improved over the study with a pronounced improvement for new to treatment patients. Across the study, 76% of participants had no illicit opioid use. Data from the four Australian sites will be presented as a sub-group analysis.

**Discussions and Conclusions:**
CAM2038 demonstrated safety, tolerability across 48-weeks and may be an effective OUD treatment.

**Implications for Practice or Policy** (optional)**:**
The introduction of flexible-dose depot buprenorphine has significant implications in enhancing access to treatment, especially for people who have problems sustaining supervised dosing.

**Disclosure of Interest Statement:**
*NL has received untied educational grants from Reckitt Benckiser and Indivior for investigator led research related to buprenorphine.*

*NL, AD, PH, RA were investigators in the study sponsored by Braeburn Pharmaceuticals (no personal grants or consultancy received from either Camurus or Braeburn Pharmaceuticals)*